Aptamer regulated nucleic acids and uses thereof

US9315862B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9315862-B2
Application numberUS-24388905-A
CountryUS
Kind codeB2
Filing dateOct 5, 2005
Priority dateOct 5, 2004
Publication dateApr 19, 2016
Grant dateApr 19, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention relates to trans-acting ligand-responsive nucleic acids and uses thereof. In particular, a ligand responsive nucleic acid comprises an effector domain and an aptamer domain that is responsive to a ligand.

First claim

Opening claim text (preview).

We claim: 1. A nucleic acid comprising (i) a substrate sequence that can form a hairpin RNA stem as a substrate for an RNaseIII family nuclease, and (ii) an aptamer that binds to a ligand, wherein said aptamer comprises a sequence that can form an aptamer stem, the formation of said aptamer stem competes with the formation of said hairpin RNA stem, wherein binding of the ligand to said aptamer causes a conformational change to render the substrate sequence non-functional by destabilizing the hairpin RNA stem, through stabilizing the aptamer stem, and, wherein said RNaseIII family nuclease processes said hairpin RNA through an RNA interference (RNAi) mechanism in attenuating expression of a target gene. 2. The nucleic acid of claim 1 , wherein said nucleic acid is a ribonucleic acid (RNA). 3. The nucleic acid of claim 1 , wherein said RNaseIII family nuclease processes said hairpin RNA to produce siRNA. 4. The nucleic acid of claim 1 , wherein the ligand is a small molecule having a molecular weight less than 2500 amu. 5. The nucleic acid of claim 1 , wherein the ligand is a metal ion. 6. The nucleic acid of claim 1 , wherein the ligand is a polypeptide, a peptide, a nucleic acid, a carbohydrate, a fatty acid, a lipid, a non-peptide hormone, or a metabolic precursor or product thereof. 7. The nucleic acid of claim 1 , wherein the ligand is selected from enzyme co-factors, enzyme substrates and products of enzyme-mediated reactions. 8. An expression construct comprising (i) a coding sequence which, when transcribed, produces the RNA of claim 2 , and (ii) one or more transcriptional regulatory sequences that regulate transcription of said RNA in a cell containing said expression construct. 9. A library of aptamer-regulated nucleic acids, each independently comprising the nucleic acid of claim 1 , or an expression construction encoding said nucleic acid. 10. A recombinant cell engineered with the expression construct of claim 9 . 11. A cell comprising the nucleic acid of claim 1 . 12. The nucleic acid of claim 1 , wherein said RNaseIII family nuclease is Dicer. 13. The nucleic acid of claim 3 , wherein said siRNA is between about 19 and about 30 nucleotides in length. 14. The nucleic acid of claim 3 , wherein said siRNA is between about 21 and about 23 nucleotides in length. 15. The nucleic acid of claim 1 , wherein said nucleic acid further comprises an intercalator or an alkylating agent. 16. The nucleic acid of claim 1 , wherein said aptamer is responsive to pH, temperature, or salt concentration. 17. The nucleic acid of claim 1 , wherein said aptamer of said nucleic acid is altered so that the K d for binding of a ligand to the aptamer is higher or lower than the K d of an unaltered aptamer. 18. The nucleic acid of claim 1 , wherein said nucleic acid comprises one or more said aptamers or one or more said substrate sequences. 19. The nucleic acid of claim 1 , wherein said nucleic acid interacts with and responds to multiple ligands. 20. The nucleic acid of claim 1 , wherein said nucleic acid is a cooperative ligand controlled nucleic acid wherein multiple ligands sequentially bind to multiple aptamer domains to allosterically regulate an effector domain.

Assignees

Inventors

Classifications

  • for hyperglycaemia, e.g. antidiabetics · CPC title

  • Immunostimulants · CPC title

  • Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

  • interfering nucleic acids [NA] · CPC title

  • Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9315862B2 cover?
The invention relates to trans-acting ligand-responsive nucleic acids and uses thereof. In particular, a ligand responsive nucleic acid comprises an effector domain and an aptamer domain that is responsive to a ligand.
Who is the assignee on this patent?
Smolke Christina D, Bayer Travis S, California Inst Of Techn
What technology area does this patent fall under?
Primary CPC classification C12Q1/686. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Apr 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).